Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Other hematologic neoplasm 9Thoracic 8Lymphoid 6Gynecologic 5CNS 5Breast 4Tumor-Agnostic 3Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1Endocrine 1Classical hematology 1

Conditions

Myeloproliferative Syndrome, Transient 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 21Methotrexate 16Hydroxyurea 15Cyclophosphamide 15Busulfan 15Peripheral Blood Stem Cell Transplantation 13ruxolitinib 11Etoposide 11Whole-Body Irradiation 10fludarabine phosphate 9fludarabine 9Tacrolimus 9Mycophenolic Acid 9Daunorubicin 9Idarubicin 8Radiotherapy 7Mitoxantrone 7Interferon-alpha 7Cyclosporine 6peginterferon alfa-2a 5bosutinib 5asciminib 5Melphalan 5Azacitidine 5merphos 4luspatercept 4Thioguanine 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Observation × Myeloid × Clear all
NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Children's Oncology Group

Phase 3 Withdrawn
MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡